Sickle cell disease targeted with CRISPR therapy as ‘the only potential cure’

sickle cell crispr x wide e cc c b f b f ecb e
Victoria Gray. Image: Meredith Rizzo/NPR

[F]or the first time, doctors in the United States used the gene editing tool CRISPR to attempt to remedy a genetic disease in a living person. Victoria Gray, a 41-year-old woman from Mississippi was born with sickle cell disease, an often painful and debilitating condition caused by a genetic mutation that alters the shape of red blood cells. As of now, only one treatment for the condition exists—a donor transplant that works for just 10 percent of patients—but doctors think editing cells extracted from Gray’s own bone marrow could restore proper red blood cell formation. If successful, it could prove to be the treatment 90 percent of sickle cell patients have been waiting for.

[R]esearchers will have to watch Gray and other patients for at least 15 years, [hematologist Vivien] Sheehan says, possibly longer. It could take that long to understand if fetal hemoglobin is a long-term solution and to see if there are any unintentional effects from using CRISPR.

It’s too early to draw conclusions but researchers are still eager, because for the vast majority of people with sickle cell disease, [hematologist Vivien] Sheehan says, “this is the only potential cure.”

Read full, original post: Doctors altered a person’s genes with CRISPR for the first time in the U.S. Here’s what could be next.

Related article:  Why synthetic biology is about much more than resurrecting woolly mammoths
Outbreak Daily Digest
Biotech Facts & Fallacies
Genetics Unzipped
Infographic: How dangerous COVID mutant strains develop

Infographic: How dangerous COVID mutant strains develop

Sometime in 2019, probably in China, SARS CoV-2 figured out a way to interact with a specific "spike" on the ...

Philip Njemanze: Leading African anti-GMO activist claims Gates Foundation destroying Nigeria

Nigerian anti-GMO activist, physician, and inventor pushes anti-gay and anti-GMO ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend